
Global supply strains and patent clock push Novo Nordisk into tight corner in India’s obesity drug race
Danish pharmaceutical giant Novo Nordisk, which triggered a global rush for weight-loss drugs with its GLP-1-based therapies, is now grappling with the fallout of having underestimated the very demand it helped stimulate. The global shortage of its GLP-1- …